Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients

This trial follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron IDH1 PCR Kit and Sanger sequencing method. The results were determined independently according to the cutoff values or interpretation requirements provided by each method. Combined with the results of clinicopathological classification, the incidence of IDH1 gene R132H mutation in different subtypes was counted to evaluate the clinical performance of the Genetron IDH1 PCR Kit.

Inclusion criteria

• Enroll cases in strict accordance with the requirements of the study
• The remaining samples after routine clinical testing
• The collection and processing of samples meet the requirements of standard laboratory operations and product instructions
• The relevant information of the sample is complete, including sample number, gender, age, and possible clinical diagnosis information
• Each sample must have HE staining results (hematoxylin-eosin staining)
• Pathological examination diagnosed as glioma, other brain tumors or normal tissues
• Number of samples: 10 pieces of each sample with a thickness of 10μm, and the tumor content is not less than 50%

Exclusion criteria

• Incomplete sample information
• Severely contaminated samples
• Samples that do not meet the requirements of sample collection and processing